Potential biomarkers to follow the progression and treatment response of Huntington’s disease
Open accessThe DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
Abstract
Huntington’s disease (HD) is a rare genetic disease caused by expanded polyglutamine repeats in the huntingtin protein resulting in selective neuronal loss. Although genetic testing readily identifies those who will be affected, current pharmacological treatments do not prevent or slow down disease progression. A major challenge is the slow clinical progression and the inability to biopsy the affected tissue, the brain, making it difficult to design short and effective proof of concept clinical trials to assess treatment benefit. In this study, we focus on identifying peripheral biomarkers that correlate with the progression of the disease and treatment benefit. We recently developed an inhibitor of pathological mitochondrial fragmentation, P110, to inhibit neurotoxicity in HD. Changes in levels of mitochondrial DNA (mtDNA) and inflammation markers in plasma, a product of DNA oxidation in urine, mutant huntingtin aggregates, and 4-hydroxynonenal adducts in muscle and skin tissues were all noted in HD R6/2 mice relative to wild-type mice. Importantly, P110 treatment effectively reduced the levels of these biomarkers. Finally, abnormal levels of mtDNA were also found in plasma of HD patients relative to control subjects. Therefore, we identified several potential peripheral biomarkers as candidates to assess HD progression and the benefit of intervention for future clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. Analysis of mtDNA content in brain and plasma. (A) DNA synthetized from mouse brain tissue was used in real-time PCR with mtND2 primers targeting mouse mtDNA (n = 4 mice per group). (B) mtND2 DNA content in plasma samples from mouse blood collected at the age of 13 wk were assayed by real-time PCR (n = 10 WT and n = 8 R6/2 Tg mice). Housekeeping nuclear gene, GAPDH, was used for normalization. (C) Change in mtND2 levels over time in mice. Mouse plasma samples from WT and R6/2 mice were collected every 2 wk, and mtND2 levels were determined using real-time PCR. mtND2 levels decreased over time in R6/2 mice as compared with WT mice (n = 10 WT; n = 10 R6/2 [5–11-wk-old mice]; n = 9 [13-wk-old mice]). The data are presented as mean ± SEM of 2−ΔΔCT. *, P = 0.0006; **, P = 0.0055; ***, P = 0.00017 versus WT 5 wk; #, P = 0.00085 versus WT 7 wk; ##, P = 0.004 versus WT 13 wk (unpaired Student’s t test and one-way ANOVA).](https://figures.cochat.ai/paper-figures/a8a6377d85494b5fabba696d2812f99f/potential-biomarkers-to-follow-the-progression-and-treatment-response-of-figure-1.jpg)






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition to direct neuronal toxicity, HD pathogenesis is accompanied by significant neuroinflammation [192]. Brains impacted with HD exhibit increased microglial activation and elevated pro-inflammatory cytokine levels, including IL-6 and TNF-α [193,194].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [193]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · cited 2×
“Relative changes in gene expression was calculated using the 2−ΔΔCT method (Livak and Schmittgen, 2001), where ΔΔCT = (CT,mtND2 − CT,GAP DH)treatment − (CT,mtND2 − CT,GAP DH)control.”
MethodMACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Adams, J. L., Dinesh, K., Xiong, M., Tarolli, C. G., Sharma, S., Sheth, N., Aranyosi, A. J., Zhu, W., Goldenthal, S., Biglan, K. M., et al. (2017) · Digital Biomarkers · doi:10.1159/000479018 · Cited by 3,171
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Shah, M. A., Datson, N. A., Srinidhi, L., Stanton, V. P., MacDonald, M. E., Allard, M. W., Youngman, S., Am, F., Mott, R., Draths, K., et al. (1993) · Cell · Cited by 3,055
Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain
DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., & Aronin, N. (1997) · Science · doi:10.1126/science.277.5334.1990 · Cited by 2,439 · cited 2×
“Aggregates of mtHtt were previously reported in the brains of human HD patients (DiFiglia et al., 1997) and R6/2 mice when measured at the age of 13 wk (Guo et al., 2013).”
BackgroundHuntington's disease: from molecular pathogenesis to clinical treatment
Ross, C. A., & Tabrizi, S. J. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,743 · cited 1×
“Progressive loss of striatal and cortical neurons mediates the cognitive and motor impairments in HD patients and in R6/2 mice (Ross and Tabrizi, 2011; Guo et al., 2013).”
BackgroundMitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases
Chen, H., & Chan, D. C. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp326 · Cited by 1,458 · cited 1×
“1 C) probably reflect initially cell damage and subsequently decline in cell and/or mitochondrial number (Chen and Chan, 2009; Podlesniy et al., 2013).”
BackgroundBrowne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410514 · Cited by 885 · cited 2×
“Our data are also consistent with five of six other patient sample analyses (Browne et al., 1997; Polidori et al., 1999; Hersch et al., 2006; Chen et al., 2007; Long et al., 2012; Ciancarelli et al., 2014).”
BackgroundResultInfluential
Cited by
Joshi, A. U., Minhas, P. S., Liddelow, S. A., Haileselassie, B., Andreasson, K. I., Dorn, G. W., & Mochly-Rosen, D. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0486-0 · Cited by 571
Self-citationEvolving and Expanding the Roles of Mitophagy as a Homeostatic and Pathogenic Process
Gustafsson, Å. B., & Dorn, G. W. (2019) · Physiological Reviews · doi:10.1152/physrev.00005.2018 · Cited by 228
Haileselassie, B., Joshi, A. U., Minhas, P. S., Mukherjee, R., Andreasson, K. I., & Mochly-Rosen, D. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1689-8 · Cited by 203
Self-citationInhibition of Drp1/Fis1 interaction slows progression of amyotrophic lateral sclerosis
Joshi, A. U., Saw, N. L., Vogel, H., Cunnigham, A. D., Shamloo, M., & Mochly‐Rosen, D. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708166 · Cited by 180
“…of mitochondria with damaged cristae (P = 0.0086). mtDNA content has been previously used to assess the mitochondrial number in various diseases, including ALS, where a significant decrease was observed in the spinal cord of patients (Wiedemann et al, 2002; Kim et al, 2010; Disatnik et al, 2016).”
MethodSelf-citationJoshi, A. U., Saw, N. L., Shamloo, M., & Mochly-Rosen, D. (2018) · Oncotarget · doi:10.18632/oncotarget.23640 · Cited by 145
“The animals used in the P110 treatment study were implanted with a 28 days osmotic pump (Alzet) containing TAT47–57 carrier control peptide or P110-TAT47–57, which delivered to the mice at a rate of 3 mg/Kg/day, as described previously [67].”
MethodSelf-citationZhao, Y., Sun, X., Hu, D., Prosdocimo, D. A., Hoppel, C., Jain, M. K., Ramachandran, R., & Qi, X. (2019) · Nature Communications · doi:10.1038/s41467-019-09291-x · Cited by 113
Self-citationKornfeld, O. S., Qvit, N., Haileselassie, B., Shamloo, M., Bernardi, P., & Mochly‐Rosen, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-32228-1 · Cited by 117
Self-citationMitochondrial biogenesis as a therapeutic target for traumatic and neurodegenerative CNS diseases
Simmons, E. C., Scholpa, N. E., & Schnellmann, R. G. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113309 · Cited by 101
“, 2013), thereby hindering fusion and providing neuroprotection in several rodent models of neurodegeneration, including PD (Disatnik et al., 2013; Disatnik et al., 2016; Guo et al., 2013; Qi et al., 2013; Thornton et al., 2018).”
BackgroundScheffer, D. D. L., Garcia, A. A., Lee, L., Mochly‐Rosen, D., & Ferreira, J. C. B. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0145 · Cited by 103
“Similar protective results are observed in other degenerative diseases, including diabetes (173), Huntington’s disease (54, 76), amyotrophic lateral sclerosis (102), Parkinson’s disease (67, 159), and Alzheimer’s disease (101).”
Self-citationMeloni, B. P., Mastaglia, F. L., & Knuckey, N. W. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00108 · Cited by 92
Ríos, L., Pokhrel, S., Li, S., Heo, G., Haileselassie, B., & Mochly‐Rosen, D. (2023) · Nature Communications · doi:10.1038/s41467-023-40043-0 · Cited by 85
Self-citationInflammation in Huntington's disease: A few new twists on an old tale
Valadão, P. A. C., Almeida‐Santos, A. F., Ferreira-Vieira, T. H., Cordeiro, T. M. E., Teixeira, A. L., Guatimosim, C., & de Miranda, A. S. (2020) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2020.577380 · Cited by 84
Zhang, G., Wei, H., Zhao, A., Xu, Y., Zhang, X., Gan, J., Guo, M., Wang, J., Zhang, F., Jiang, Y., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03363-0 · Cited by 88
Joshi, A. U., Ebert, A., Haileselassie, B., & Mochly‐Rosen, D. (2018) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2018.12.004 · Cited by 72
“Materials and Methods 2.1 Peptides Drp1/Fis1 interaction peptide inhibitor, P110, and control peptide (used for peptide delivery, TAT47-57) were synthesized by Ontores Biotechnologies (Hangzhou, China) (15).”
BackgroundMethodSelf-citationNeuroinflammation in Huntington’s disease: From animal models to clinical therapeutics
Jia, Q., Li, S., Li, X.-J., & Yin, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1088124 · Cited by 70
“also measured the levels of inflammatory cytokines such as TNF and IL-6, the levels of both these cytokines were two times higher in the plasma of 13 weeks old R6/2 mice than WT mice (39).”
BackgroundMitochondrial HSF1 triggers mitochondrial dysfunction and neurodegeneration in Huntington's disease
Liu, C., Fu, Z., Wu, S., Wang, X., Zhang, S., Chu, C., Hong, Y., Wu, W., Chen, S., Jiang, Y., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202215851 · Cited by 80
“Increasing lines of evidence have shown that mtDNA deletion contributes to the pathogenesis of HD (Horton et al, 1995; Disatnik et al, 2016).”
BackgroundMortal engines: Mitochondrial bioenergetics and dysfunction in neurodegenerative diseases
Joshi, A. U., & Mochly‐Rosen, D. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.010 · Cited by 58
“Molecular biology of the cell 2013;24(5):659–667.”
BackgroundInfluentialSelf-citationReddy, D. S., & Abeygunaratne, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911734 · Cited by 65
Joshi, D. C., Chavan, M. B., Gurow, K., Gupta, M., Dhaliwal, J. S., & Ming, L. C. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117827 · Cited by 68
Mitochondrial dynamics, mitophagy and biogenesis in neonatal hypoxic‐ischaemic brain injury
Thornton, C., Jones, A., Nair, S., Aabdien, A., Mallard, C. E., & Hagberg, H. (2017) · FEBS Letters · doi:10.1002/1873-3468.12943 · Cited by 62
Askeland, G., Dosoudilova, Z., Rodinova, M., Klempir, J., Liskova, I., Kuśnierczyk, A., Bjørås, M., Nesse, G., Klungland, A., Hansikova, H., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-27985-y · Cited by 54
Simmons, D. A., James, M. L., Belichenko, N. P., Semaan, S., Condon, C., Kuan, J., Shuhendler, A. J., Miao, Z., Chin, F. T., & Longo, F. M. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy202 · Cited by 46
Biomarkers: Role and Scope in Neurological Disorders
Sharma, V., Singh, T. G., Mehta, V., & Mannan, A. (2023) · Neurochemical Research · doi:10.1007/s11064-023-03873-4 · Cited by 51
Allowitz, K. V., Taylor, J., Harames, K., Yoo, J., Baloch, O. A., & Ramana, K. V. (2024) · Current Neuropharmacology · doi:10.2174/011570159x342720241014164650 · Cited by 43
“…that these lipid aldehydes are involved in the pathophysiology of neuro-degenerative disorders, and indeed, some studies indicate that they could act as biomarkers of Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Huntington’s disease (HD) [16-21].”
Drugging DNA Damage Repair Pathways for Trinucleotide Repeat Expansion Diseases
Benn, C., Gibson, K. R., & Reynolds, D. S. (2021) · Journal of Huntington s Disease · doi:10.3233/jhd-200421 · Cited by 39
mtDNA Maintenance and Alterations in the Pathogenesis of Neurodegenerative Diseases
Shang, D., Huang, M., Wang, B., Yan, X., Wu, Z., & Zhang, X. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220810114644 · Cited by 51
“…fibroblasts) real-time quantitative PCR leukocytes and dermal fibroblasts [160] mtDNA deletion ↓mtDNA (MT-ND2) real-time PCR brain and plasma [158] mtDNA deletion ↑mtDNA lesion frequency and ↓mtDNA abundance quantitative PCR brain tissue [159] mtDNA mutation ↑mtDNA heteroplasmies sensitive…”
Molecular Mechanisms Underlying Muscle Wasting in Huntington’s Disease
Bozzi, M., & Sciandra, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218314 · Cited by 39
“Huntingtin positive aggregates were also found at the periphery of muscle fibers that also showed the presence of non-muscle nuclei, indicative of inflammatory cells infiltrations [85].”
BackgroundWhat, When and How to Measure—Peripheral Biomarkers in Therapy of Huntington’s Disease
Przybył, Ł., Woźna, M., Kozłowska, E., & Fiszer, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041561 · Cited by 34
“One example of a biomarker developed in animal studies and its transfer to patients is a study using HD R6/2 mice in which the treatment with an inhibitor of mitochondrial fragmentation, P110, resulted in the restoration of mitochondrial DNA (mtDNA) levels in plasma [45].”
BackgroundPlatelet-derived extracellular vesicles in Huntington’s disease
Denis, H. L., Lamontagne-Proulx, J., St-Amour, I., Mason, S. L., Weiss, A., Chouinard, S., Barker, R. A., Boilard, E., & Cicchetti, F. (2018) · Journal of Neurology · doi:10.1007/s00415-018-9022-5 · Cited by 32
Protein glycosylation in urine as a biomarker of diseases
Xu, M., Yang, A., Xia, J., Jiang, J., Liu, C., Ye, Z., Ma, J., & Yang, S. (2022) · Translational research · doi:10.1016/j.trsl.2022.08.001 · Cited by 33
Mukherjee, R., Tompkins, C. A., Ostberg, N. P., Joshi, A. U., Massis, L. M., Vijayan, V., Gera, K., Monack, D. M., Cornell, T. T., Hall, M. W., et al. (2022) · Critical Care Medicine · doi:10.1097/ccm.0000000000005437 · Cited by 31
“We also recognize that, although there are significant preclinical efficacy and safety data for peptide P110 (44), future studies are necessary to validate this therapeutic target.”
BackgroundSelf-citationSimmons, D. A., Mills, B. D., Butler, R. R., Kuan, J., McHugh, T. L. M., Akers, C. S., Zhou, J., Syriani, W., Goubran, M., Zeineh, M., et al. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01023-8 · Cited by 31
The Expanding Clinical Universe of Polyglutamine Disease
Huang, S., Zhu, S., Li, X., & Li, S. (2019) · The Neuroscientist · doi:10.1177/1073858418822993 · Cited by 22
Circulating hsa-miR-323b-3p in Huntington's Disease: A Pilot Study
Ferraldeschi, M., Romano, S., Giglio, S., Romano, C., Morena, E., Mechelli, R., Annibali, V., Ubaldi, M., Buscarinu, M. C., Umeton, R., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.657973 · Cited by 20
“Following approaches focused on more accessible fluids, such as blood, and several studies reported informative results: plasma levels of 24S-hydroxychiolesterol (6, 7), mitochondrial DNA (mtDNA) (8), and neurofilament light protein (NFL) were described as potential biomarkers in HD.”
BackgroundInfluentialBečanović, K., Asghar, M., Gadawska, I., Sachdeva, S., Walker, D., Lazarowski, E. R., Franciosi, S., Park, K. H. J., Côté, H. C. F., & Leavitt, B. R. (2021) · npj Aging and Mechanisms of Disease · doi:10.1038/s41514-021-00079-2 · Cited by 19
Self-citationInflammasome activation and assembly in Huntington’s disease
Furlam, T. D. O., Roque, I. G., da Silva, E. W. M., Vianna, P. P., Valadão, P. A. C., Guatimosim, C., Teixeira, A. L., & de Miranda, A. S. (2022) · Molecular Immunology · doi:10.1016/j.molimm.2022.09.002 · Cited by 18
Lin, A. J., Joshi, A. U., Mukherjee, R., Tompkins, C. A., Vijayan, V., Mochly‐Rosen, D., & Haileselassie, B. (2021) · Shock · doi:10.1097/shk.0000000000001885 · Cited by 18
Self-citationCurrent Diagnostic Methods and Non-Coding RNAs as Possible Biomarkers in Huntington’s Disease
Pellegrini, M., Bergonzoni, G., Perrone, F., Squitieri, F., & Biagioli, M. (2022) · Genes · doi:10.3390/genes13112017 · Cited by 16
Li, S., Tetri, L. H., Vijayan, V., Elezaby, A., Chiang, C.-H., Lopez, I., Ostberg, N. P., Cornell, T. T., Chen, C., & Haileselassie, B. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123658 · Cited by 8
Cellular mechanisms of acute rhabdomyolysis in inherited metabolic diseases
de Calbiac, H., Imbard, A., & de Lonlay, P. (2024) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12781 · Cited by 9
Zadel, M., Maver, A., Kovanda, A., & Peterlin, B. (2018) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2017.0206 · Cited by 8
“…as systemic events in HD both in transcriptomic (Hensman Moss et al., 2017; Mastrokolias et al., 2015; Runne et al., 2007) and physiological studies (Bezprozvanny and Hayden, 2004; Bjo¨rkqvist et al., 2008; Cui et al., 2006; Disatnik et al., 2016; Islam, 2017; Kwan et al., 2012; Tai et al., 2007).”
Lowering mutant huntingtin by small molecules relieves Huntington’s disease symptoms and progression
Bahat, A., Itzhaki, E., Weiss, B., Tolmasov, M., Tsoory, M., Kuperman, Y., Brandis, A. S., Shurrush, K. A., & Dikstein, R. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-023-00020-y · Cited by 7
“…also associated with impaired mitochondrial integrity and excessive mitochondrial fi ssion (Hwang et al, 2015) resulting in a decline in the level of the mtDNA in the brain and plasma of HD patients (by >50% in severe HD patients), as well as in HD mice model (Guo et al, 2013; Disatnik et al, 2016).”
The Role of Cell-Free Circulating DNA in the Diagnosis and Prognosis of Breast Cancer
Hosseinalizadeh, H., Mahmoodpour, M., & Ebrahimi, A. (2021) · Annals of Cancer Research and Therapy · doi:10.4993/acrt.29.169 · Cited by 4
Szejko, N., Picón, C., García‐Caldentey, J., de Yébenes, J. G., Alvarez-Cermeño, J. C., Villar, L. M., & López-Sendón, J. L. (2018) · PLoS Currents · doi:10.1371/currents.hd.280c8f9f7d9fa4f7f0c883d9f8e807da · Cited by 4
Dontiboina, H. R., Yadava, S., Nakka, V. P., Dumala, N., Viswanadh, M. K., Guntupalli, C., Nalluri, B. N., Malothu, N., Yadagiri, G., Gujjari, L., et al. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05967-w · Cited by 3
Danna, R., Kondle, S., Amar, O., Mabourakh, M., Chen, G., Fadol, W. B., & Mohieldin, A. M. (2025) · Biology · doi:10.3390/biology14121787 · Cited by 2
“Brains impacted with HD exhibit increased microglial activation and elevated pro-inflammatory cytokine levels, including IL-6 and TNF-α [193,194].”
Resistance Training Protects against Cardiac Damage in Doxorubicin-Induced Cardiotoxicity in Rats
Sequeira, C. M., Evangelista, J. F., Alves, R., Nascimento, A. L. R., & Matsuura, C. (2025) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000003809 · Cited by 2
Mitochondrial/Oxidative Stress Biomarkers in Huntington’s Disease
Kepková, K. V., & Vodička, P. (2023) · Contemporary clinical neuroscience · doi:10.1007/978-3-031-32815-2_13 · Cited by 2
Mitochondria: A source of potential biomarkers for non-communicable diseases
Ichegiri, A., Kodolikar, K., Bagade, V., Selukar, M., & Dey, T. (2024) · Advances in clinical chemistry · doi:10.1016/bs.acc.2024.04.007 · Cited by 3
Senescence and Neurodegenerative Disorders: Beyond Alzheimer’s and Parkinson’s
Tiwari, I., Chauhan, P., Singh, A., & Sharma, N. K. (2025) · Springer eBooks · doi:10.1007/978-981-96-1041-9_7 · Cited by 1
Cerebrospinal Fluid Biomarkers in Huntington’s Disease
Pio, F., & Leavitt, B. R. (2023) · Contemporary clinical neuroscience · doi:10.1007/978-3-031-32815-2_2 · Cited by 1
Self-citationInflammation Biomarkers in Huntington’s Disease
Björkqvist, M. (2023) · Contemporary clinical neuroscience · doi:10.1007/978-3-031-32815-2_11 · Cited by 1
Malik, A. N. (2018) · Wiley eBooks · doi:10.1002/9781119329725.ch25 · Cited by 3
Role of Extracellular Vesicles on Immune Regulation in an Animal Model of Multiple Sclerosis
Willis, C. M. (2019) · OpenCommons - UConn (University of Connecticut)
Wang, X. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736650668.793565579
Skin Biomarkers of Neurodegenerative Diseases
Reilly-Jankowiak, L., Bargar, C., Bunn, D., & Chen, S. G. (2025) · Springer eBooks · doi:10.1007/978-3-031-66513-4_6
Gil‐Salcedo, A., Massart, R., Youssov, K., Morgado, G., & Bachoud‐Lévi, A. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13717-0
“However, the link between these eventual combinations and the progression of HD remain unclear [13, 14, 30].”
InfluentialDeng, R., Silva, T. D. O., Liu, X., Fan, C., Seok, H. Y., Wu, J., Wickramage, I., Guo, H., Lin, T., Zhang, S., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.06.033 · Cited by 2
Metadata
- Authors
- Disatnik, M.-H., Joshi, A. U., Saw, N. L., Shamloo, M., Leavitt, B. R., Qi, X., & Mochly-Rosen, D.
- Affiliations
- Stanford Medicine (US)
- University of British Columbia (CA)
- Case Western Reserve University (US)
- Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA 94305 1
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2016-11-07
- Volume
- 213
- Issue
- 12
- Pages
- 2655-2669
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC5110026
- OpenAlex
- W2554473742
- Cited by
- 58
- References
- 69
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 4 · 2023: 5 · 2022: 9 · 2021: 6 · 2020: 6 · 2019: 5 · 2018: 11 · 2017: 2
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (HL52141)
- TAKEDA Pharmaceuticals U.S.A.
- NIH (R01 NS088192)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- Huntington's disease, peripheral biomarkers, disease progression, treatment response, p110, mitochondrial fragmentation, mitochondrial DNA, oxidative DNA damage, 4-hydroxynonenal, mutant huntingtin aggregates, neuroinflammation, R6/2 mice, plasma biomarkers, clinical trial endpoints
- MeSH terms
- Aldehydes, Animals, Behavior, Animal, Body Fluids, Brain, DNA Damage, DNA, Mitochondrial, Humans, Huntington Disease, Inflammation, Mitochondria, Oxidation-Reduction, Phenotype, Biomarkers, Case-Control Studies, Disease Progression, Muscle, Skeletal, Mice, Protein Aggregates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.